Triple threat: new combo aims to turn inoperable lung cancer into surgical candidates
NCT ID NCT07131319
First seen Feb 02, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tests whether a special type of radiation (SFRT) combined with the immunotherapy drug tislelizumab and standard chemotherapy can shrink stage III lung cancer enough to allow surgery. About 30 adults with initially unresectable non-small cell lung cancer will receive this combination as an induction treatment. The main goal is to see how many patients can then have their tumor surgically removed, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanchang City, Jiangxi Province
RECRUITINGNanchang, Jiangxi, 330000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.